Roflumilast
Cat.No:IR1100 Solarbio
CAS:162401-32-3
Molecular Formula:C17H14Cl2F2N2O3
Molecular Weight:403.21
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Metabolic Enzyme & Protease > RoflumilastCAS:162401-32-3
Molecular Formula:C17H14Cl2F2N2O3
Molecular Weight:403.21
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
| CAS | 162401-32-3 |
| Name | Roflumilast |
| Molecular Formula | C17H14Cl2F2N2O3 |
| Molecular Weight | 403.21 |
| Solubility | Soluble in DMSO ≥5mg/mL;Soluble in Water < 0.1mg/mL |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
| EC | EINECS 223-583-8 |
| MDL | MFCD00938270 |
| SMILES | O=C(NC1=C(Cl)C=NC=C1Cl)C2=CC=C(OC(F)F)C(OCC3CC3)=C2 |
| Target Point | Phosphodiesterase (PDE) |
| Passage | Metabolic Enzyme&Protease |
| Background | Roflumilast is a selective PDE4 inhibitor. |
| Biological Activity | Roflumilast 是一种选择性的 PDE4 抑制剂,作用于 PDE4A1,PDEA4,PDEB1 和 PDEB2,IC50 分别为 0.7,0.9,0.7 和 0.2 nM。[1-5] |
| IC50 | 0.7nM(PDE4A1),0.9nM(PDE4A4),0.7nM(PDE4B1),0.2nM(PDE4B2)[1] |
| Data Literature Source | [1]. Hatzelmann A,et al. The preclinical pharmacology of roflumilast--a selective,oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. [2]. Rabe KF. Update on roflumilast,a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011 May;163(1):53-67. [3]. Hatzelmann A,et al. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001 Apr;297(1):267-79. [4]. Richmond BW,et al. Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency. Nat Commun. 2016 Apr 5;7:11240. [5]. Ding H,et al. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast. Int Urol Nephrol. 2017 Jul 29 |
| Unit | Bottle |
| Specification | 5mg 10mg 25mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download